Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2003

View Archived Issues

AVI BioPharma plans second AVI-4020 study for West Nile virus

CytRx to fund UMMS research program of RNAi silencing for ALS

Investigator meeting precedes phase II study of ProCord

Doripenem similarly effective against ESBL- and non-ESBL-producing bacteria

New analgesic agents identified by Schwarz researchers

GSK antiangiogenic Tie-2 and/or VEGFR2 inhibitors covered by patent

Novel RT inhibitors prepared and tested at the U. of Pittsburgh and Fluorous Technologies

PPAR modulators and their use presented in recent patents

New Abeta production inhibitors/sAPPalpha secretion enhancers discovered at Takeda

U. of Tennessee team claims novel androgen receptor antagonists

Recombinant alpha1-antitrypsin enters proof-of-concept study for atopic dermatitis

Liprostin trial commences in Georgia

Proteasome inhibitor improves renovascular responses in hypercholesterolemic pigs

Thymitaq designated orphan drug in E.U. for liver cancer

License agreement for use of Amplivax in novel HIV vaccine candidate

Kyowa Hakko licenses KW-3902 rights to NovaCardia

Millennium commences phase I/II study of MLN-2704 in prostate cancer

Inspra approved for congestive heart failure in heart attack patients

Approvable letter for Savient's osteoarthritis pain product

YKP-1358 cleared to enter clinical testing

Bactericidal activity of oritavancin reported at IDSA meeting

Fast track status for TNX-355

Data discussed at IDSA support further development of dalbavancin

Safety and pharmacokinetics of single-dose oral glutamine in pediatric oncology patients

Darifenacin has beneficial effects in bladder function disorders

Good efficacy and tolerability described for solifenacin in overactive bladder patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...